Base de dados : MEDLINE
Pesquisa : C11.768 [Categoria DeCS]
Referências encontradas : 17704 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1771 ir para página                         

  1 / 17704 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27772648
[Au] Autor:Nesper PL; Simjanoski E; Mirza RG
[Ad] Endereço:Department of Ophthalmology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
[Ti] Título:Retinal Macroaneurysm in Long-Standing Hypertension.
[So] Source:Ophthalmology;123(11):2327, 2016 11.
[Is] ISSN:1549-4713
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Aneurisma/etiologia
Hipertensão/complicações
Artéria Retiniana/patologia
Doenças Retinianas/etiologia
[Mh] Termos MeSH secundário: Idoso
Aneurisma/diagnóstico por imagem
Arteríolas/diagnóstico por imagem
Arteríolas/patologia
Feminino
Angiofluoresceinografia
Seres Humanos
Artéria Retiniana/diagnóstico por imagem
Doenças Retinianas/diagnóstico por imagem
Hemorragia Retiniana/diagnóstico
Líquido Sub-Retiniano
Tomografia de Coerência Óptica
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  2 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29486762
[Au] Autor:Schmid MK; Reich O; Blozik E; Faes L; Bodmer NS; Locher S; Thiel MA; Rapold R; Kuhn M; Bachmann LM
[Ad] Endereço:University of Zurich, Zurich, Switzerland.
[Ti] Título:Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.
[So] Source:BMC Ophthalmol;18(1):64, 2018 Feb 27.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. METHODS: We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye clinic in Switzerland between January 1st and December 31st 2016 who were insured in one of the two participating health insurance companies. Clinical data were extracted from the electronic health record system. The health insurers provided the health claim costs for the ophthalmologic care and the total health care costs of each patient in the observation period. Using multivariate regression models, we assessed the monthly ophthalmologic and the monthly total costs of patients with no history of switching (ranibizumab vs. aflibercept), patients with a history of switching from ranibizumab to aflibercept, patients switching during the observation period and a miscellaneous group. We examined baseline differences in age, proportion of males, visual acuity (letters), central retinal thickness (CRT) and treatment history before entering the study. We investigated treatment intensity and compared the changes in letters and CRT. RESULTS: The analysis involved 488 eyes (361 patients), 182 on ranibizumab treatment, and 63 on aflibercept treatment, 160 eyes with a history of switching from ranibizumab to aflibercept, and 45 switchers during follow-up and 38 eyes of the miscellaneous group. Compared to ranibizumab, monthly costs of ophthalmologic treatment were slightly higher for aflibercept treatment + 175.0 CHF (95%CI: 1.5 CHF to 348.3 CHF; p = 0.048) as were the total monthly costs + 581.0 CHF (95%CI: 159.5 CHF to 1002.4 CHF; p = 0.007). Compared to ranibizumab, the monthly treatment intensity with aflibercept was similar (+ 0.057 injections/month (95%CI -0.023 to 0.137; p = 0.162), corresponding to a projected annual number of 5.4 injections for ranibizumab vs. 6.1 injections for aflibercept. During follow-up, visus dropped by 0.7 letters with ranibizumab and increased by 0.6 letters with aflibercept (p = 0.243). CRT dropped by - 14.9 µm with ranibizumab and by - 19.5 µm with aflibercept (p = 0.708). The monthly costs of all other groups examined were higher. CONCLUSION: These real-life data show that aflibercept treatment is equally expensive, and clinical outcomes between the two drugs are similar.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/economia
Custos de Cuidados de Saúde
Ranibizumab/economia
Proteínas Recombinantes de Fusão/economia
Doenças Retinianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Inibidores da Angiogênese/uso terapêutico
Feminino
Pesquisa sobre Serviços de Saúde
Seres Humanos
Masculino
Meia-Idade
Análise Multivariada
Ranibizumab/uso terapêutico
Receptores de Fatores de Crescimento do Endotélio Vascular/uso terapêutico
Proteínas Recombinantes de Fusão/uso terapêutico
Doenças Retinianas/economia
Acuidade Visual
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (Recombinant Fusion Proteins); 15C2VL427D (aflibercept); EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180301
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0731-4


  3 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29361927
[Au] Autor:Lin Z; Feng X; Zheng L; Moonasar N; Shen L; Wu R; Chen F
[Ad] Endereço:The Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, No. 270 West College Road, Wenzhou, Zhejiang, 325027, China.
[Ti] Título:Incidence of endophthalmitis after 23-gauge pars plana vitrectomy.
[So] Source:BMC Ophthalmol;18(1):16, 2018 Jan 23.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Endophthalmitis is a rare but severe complication following PPV. The incidence of endophthalmitis varies between 20-gauge, 23-gauge, and 25-gauge incisions. The incidence and clinical features of endophthalmitis after 23-gauge PPV in an eye hospital in China was reported in this study. METHODS: Data of the eyes that underwent 23-gauge PPV from January 2011 to December 2014 at the Eye Hospital of Wenzhou Medical University was retrospectively collected. All the information was obtained from the electronic medical system. The exclusion criteria included: (1) preoperative diagnosis of endophthalmitis; (2) history of vitrectomy; (3) intraocular surgery within 6 months; (4) history of ocular penetrating trauma; (5) sutures for any of the 3 sclerotomy incisions; (6) patients with cancer, acquired immune deficiency syndrome, or taking drugs that may influence the immune system. The diagnosis of endophthalmitis was based on clinical characteristics and/or culture results from an operative sample. RESULTS: Three thousand nine hundred seventy nine eyes that underwent 23-gauge PPV surgery were included in this study. Among these eyes, 3 eyes developed endophthalmitis after surgery, giving an incidence of 0.075% (3/3979). The period in which endophthalmitis developed ranged from 1 to 5 days post-operation. The visual acuity decreased to hand motions or light perception postoperatively. The culture of aqueous and vitreous of the 2 eyes revealed Staphylococcus epidermidis and enterococcus faecalis respectively, however was negative for the third eye. All 3 eyes had a favorable response to the treatment of vitreous tap and intravitreal antibiotics injection. Two eyes gained visual acuity of 0.05 and 0.5, respectively at the final visit. CONCLUSIONS: Endophthalmitis is a rare but sight-threatening complication after 23-gauge pars plana vitrectomy. The peak duration of onset was within 5 days post-operation, with gram positive cocci being the common pathogenic organism.
[Mh] Termos MeSH primário: Endoftalmite/epidemiologia
Infecções Oculares Bacterianas/epidemiologia
Microcirurgia/efeitos adversos
Doenças Retinianas/cirurgia
Infecções Estafilocócicas/epidemiologia
Infecção da Ferida Cirúrgica/epidemiologia
Vitrectomia/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Idoso
Humor Aquoso/microbiologia
China/epidemiologia
Endoftalmite/diagnóstico
Endoftalmite/microbiologia
Enterococcus faecalis/isolamento & purificação
Infecções Oculares Bacterianas/diagnóstico
Infecções Oculares Bacterianas/microbiologia
Feminino
Seguimentos
Infecções por Bactérias Gram-Positivas/diagnóstico
Infecções por Bactérias Gram-Positivas/epidemiologia
Infecções por Bactérias Gram-Positivas/microbiologia
Seres Humanos
Incidência
Masculino
Microcirurgia/instrumentação
Meia-Idade
Estudos Retrospectivos
Infecções Estafilocócicas/diagnóstico
Infecções Estafilocócicas/microbiologia
Staphylococcus epidermidis/isolamento & purificação
Infecção da Ferida Cirúrgica/microbiologia
Ultrassonografia
Acuidade Visual
Vitrectomia/instrumentação
Corpo Vítreo/diagnóstico por imagem
Corpo Vítreo/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0678-5


  4 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351793
[Au] Autor:Jiang Y; Brenner JE; Foster WJ
[Ad] Endereço:Department of Ophthalmology, Temple University, 3401 N Broad Street, 6th Floor Parkinson Pavilion, Philadelphia, PA, 19140, USA.
[Ti] Título:Retinal complications of gout: a case report and review of the literature.
[So] Source:BMC Ophthalmol;18(1):11, 2018 Jan 19.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: There have been few reported findings of posterior segment complications of gout. While exudative lesions, an increased risk of macular degeneration, and vascular occlusions have been previously reported, to our knowledge, refractile macular lesions have not been reported in a patient with chronic uncontrolled gout. CASE PRESENTATION: Highly refractile, crystal-like lesions were found in the macula of a 62 year old male patient with chronically uncontrolled gout. The lesions appeared at the termination of retinal arterioles and were located at the level of the retinal pigment epithelium. The lesions did not stain with fluorescein and were associated with larger areas geographic atrophy. Review of the patient's blood tests revealed well-controlled vasculopathic risk factors. Fundus appearance and best-corrected visual acuity remained stable over 12 months of follow-up during which the uric acid levels were well controlled. CONCLUSION: Retinopathy may be associated with chronically uncontrolled gout and patients with visual complaints should undergo a dilated examination in addition to the typical anterior segment slit-lamp exam.
[Mh] Termos MeSH primário: Segmento Anterior do Olho/diagnóstico por imagem
Gota/complicações
Macula Lutea/diagnóstico por imagem
Doenças Retinianas/etiologia
Vasos Retinianos/diagnóstico por imagem
[Mh] Termos MeSH secundário: Angiofluoresceinografia/métodos
Fundo de Olho
Gota/sangue
Seres Humanos
Masculino
Meia-Idade
Doenças Retinianas/diagnóstico
Tomografia de Coerência Óptica/métodos
Ácido Úrico/sangue
Acuidade Visual
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
268B43MJ25 (Uric Acid)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180121
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0669-6


  5 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334924
[Au] Autor:Zhao C; Dong F; Gao F; Liu X; Pei M; Jia S; Zhang M
[Ad] Endereço:Ophthalmology Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China.
[Ti] Título:Longitudinal observation of subretinal fibrosis in Vogt-Koyanagi-Harada disease.
[So] Source:BMC Ophthalmol;18(1):6, 2018 Jan 15.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Subretinal fibrosis (SRF) is a vision-threatening complication of Vogt-Koyanagi-Harada disease (VKH). It has long been recognized as a sequela of chronic inflammation. The developmental process of SRF, however, has not been described. The purpose of this study is to provide longitudinal observations of SRF in VKH. METHODS: Retrospective chart review of 10 VKH patients referred to our group between January 2008 and September 2015 at acute uveitic stage with SRF at presentation or who developed SRF during follow up. RESULTS: Ten patients (6 males and 4 females) with a median age of 39.0 (range, 23 to 58) years old were included. The median disease duration at presentation and median duration of follow up were 25.5 (range 5 to 60) days and 32.5 (range 13 to 61) months respectively. At presentation, all patients except one had been inappropriately treated with glucocorticosteroid (insufficiently dosed or tapered too fast) for longer than 2 weeks. Despite large dose oral glucocorticosteroid (1 mg/kg/d prednisone or equivalent) with slow tapering in combination with at least one immunomodulatory agent (cyclosporin A, cyclophosphamide or azathioprine) after presentation, all patients developed bilateral SRF within the first 4 months of disease course and 7 patients within the first 2 months. In 8 patients, shape-change/migration and progressive proliferation/pigmentation of SRF was observed over a period of several months after its formation, and then became quiescent but may further underwent depigmentation or pigmentation. SRF involved macula in 12 eyes (7 patients) and caused treatment resistant macular detachment and severe visual impairment in 6 eyes (4 patients). At the last visit, eyes with macular involvement were more common to had worse final best corrected visual acuity (≤20/50) than those without (9/12 vs. 0/8, p = 0.001). CONCLUSIONS: SRF usually develop early in the disease course in VKH patients who are not adequately controlled; it usually undergoes a highly dynamic process within the subretinal space and may involve the macula and resulted in poor final visual outcome.
[Mh] Termos MeSH primário: Macula Lutea/patologia
Doenças Retinianas/etiologia
Síndrome Uveomeningoencefálica/complicações
Acuidade Visual
[Mh] Termos MeSH secundário: Adulto
Feminino
Fibrose/diagnóstico
Fibrose/etiologia
Angiofluoresceinografia
Seguimentos
Fundo de Olho
Seres Humanos
Masculino
Meia-Idade
Prognóstico
Doenças Retinianas/diagnóstico
Doenças Retinianas/fisiopatologia
Estudos Retrospectivos
Fatores de Tempo
Tomografia de Coerência Óptica/métodos
Síndrome Uveomeningoencefálica/diagnóstico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0670-0


  6 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470647
[Au] Autor:Jurjevic D; Böni C; Barthelmes D; Fasler K; Becker M; Michels S; Stemmle J; Herbort C; Zweifel SA
[Ad] Endereço:Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland (Chairman: Prof. Dr. med. Klara Landau).
[Ti] Título:Torpedo Maculopathy Associated with Choroidal Neovascularization.
[Ti] Título:Torpedo-Makulopathie mit choroidaler Neovaskularisation..
[So] Source:Klin Monbl Augenheilkd;234(4):508-514, 2017 Apr.
[Is] ISSN:1439-3999
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Torpedo maculopathy is a very rare, congenital, usually unilateral hypopigmented lesion in the temporal macula. This retrospective case series describes three patients with torpedo maculopathy. The first two cases demonstrate typical clinical and imaging findings of torpedo maculopathy in asymptomatic patients. The third case relates to a symptomatic young patient with a torpedo lesion, a smaller satellite lesion, and evidence of choroidal neovascularization confirmed by fluorescence angiography. In the area of the clinically visible torpedo lesion, spectral domain optical coherence tomography showed atrophy of the outer retina with increased choroidal signalling and a hyperreflective lesion above the retinal pigment epithelium suggestive of choroidal neovascularization. Fundus autofluorescence imaging revealed a hyperautofluorescent rim along the margin of the hypoautofluorescent torpedo lesion. In the literature, torpedo lesions are usually regarded as benign lesions with no tendency for progression. The third case demonstrates that torpedo lesions may be associated with choroidal neovascularization, which has been successfully treated with anti-VEGF therapy.
[Mh] Termos MeSH primário: Neovascularização de Coroide/diagnóstico por imagem
Neovascularização de Coroide/patologia
Doenças Retinianas/diagnóstico por imagem
Doenças Retinianas/patologia
Epitélio Pigmentado da Retina/anormalidades
Epitélio Pigmentado da Retina/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Neovascularização de Coroide/complicações
Diagnóstico Diferencial
Feminino
Seres Humanos
Meia-Idade
Doenças Raras/diagnóstico
Doenças Raras/patologia
Doenças Retinianas/congênito
Epitélio Pigmentado da Retina/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-100230


  7 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29397523
[Au] Autor:Robson AG; Nilsson J; Li S; Jalali S; Fulton AB; Tormene AP; Holder GE; Brodie SE
[Ad] Endereço:Department of Electrophysiology, Moorfields Eye Hospital, 162 City Road, London, UK. anthony.robson@moorfields.nhs.uk.
[Ti] Título:ISCEV guide to visual electrodiagnostic procedures.
[So] Source:Doc Ophthalmol;136(1):1-26, 2018 02.
[Is] ISSN:1573-2622
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Clinical electrophysiological testing of the visual system incorporates a range of noninvasive tests and provides an objective indication of function relating to different locations and cell types within the visual system. This document developed by the International Society for Clinical Electrophysiology of Vision provides an introduction to standard visual electrodiagnostic procedures in widespread use including the full-field electroretinogram (ERG), the pattern electroretinogram (pattern ERG or PERG), the multifocal electroretinogram (multifocal ERG or mfERG), the electrooculogram (EOG) and the cortical-derived visual evoked potential (VEP). The guideline outlines the basic principles of testing. Common clinical presentations and symptoms are described with illustrative examples and suggested investigation strategies.
[Mh] Termos MeSH primário: Eletrodiagnóstico/normas
Eletroculografia
Eletrofisiologia/organização & administração
Eletrorretinografia/métodos
Potenciais Evocados Visuais
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Seres Humanos
Agências Internacionais
Doenças do Nervo Óptico/diagnóstico
Doenças Retinianas/diagnóstico
Sociedades Médicas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180205
[St] Status:MEDLINE
[do] DOI:10.1007/s10633-017-9621-y


  8 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29383474
[Au] Autor:Marmor MF
[Ad] Endereço:Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA. marmor@stanford.edu.
[Ti] Título:Retinopathy from hydroxychloroquine is not related to lupus or rheumatoid arthritis.
[So] Source:Doc Ophthalmol;136(1):93-94, 2018 02.
[Is] ISSN:1573-2622
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Eletrorretinografia
Hidroxicloroquina
[Mh] Termos MeSH secundário: Antirreumáticos
Artrite Reumatoide
Seres Humanos
Doenças Retinianas
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Antirheumatic Agents); 4QWG6N8QKH (Hydroxychloroquine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1007/s10633-018-9623-4


  9 / 17704 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29383473
[Au] Autor:Yesilirmak N; Telek HH; Sungur G; Ozdemir Y; Yesil NK; Ornek F
[Ad] Endereço:Department of Ophthalmology, Ankara Training and Research Hospital, Sukriye, Ulucanlar St. No: 89, Altindag, 06340, Ankara, Turkey. dryesilirmak@gmail.com.
[Ti] Título:Response to risk of hydroxychloroquine retinopathy is not related to systemic lupus erythematosus or rheumatoid arthritis.
[So] Source:Doc Ophthalmol;136(1):95-96, 2018 02.
[Is] ISSN:1573-2622
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Eletrorretinografia
Hidroxicloroquina
[Mh] Termos MeSH secundário: Artrite Reumatoide
Seres Humanos
Lúpus Eritematoso Sistêmico
Doenças Retinianas
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
4QWG6N8QKH (Hydroxychloroquine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1007/s10633-018-9624-3


  10 / 17704 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29172937
[Au] Autor:Reddy SV; Husain D
[Ad] Endereço:a Retina Service , Massachusetts Eye and Ear, Harvard Medical School , Boston , MA , USA.
[Ti] Título:Panretinal Photocoagulation: A Review of Complications.
[So] Source:Semin Ophthalmol;33(1):83-88, 2018.
[Is] ISSN:1744-5205
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Panretinal photocoagulation (PRP) is a mainstay of therapy for retinal ischemic disease. The procedure involves creating thermal burns in the peripheral retina leading to tissue coagulation, the overall consequence of which is improved retinal oxygenation. While highly effective, there have been concerns historically regarding the anatomic effects and visual complications following PRP, the most common of which include choroidal effusions, exudative retinal detachments, macular edema, visual field deficits, and night vision defects. The occurrence of these complications is closely tied to laser parameters such as increased duration and power and intensive treatment in a single sitting, all of which cause increased dispersion of thermal energy within the retina and choroid. The advent of newer laser delivery systems, such as the multispot pattern laser, has greatly mitigated but not eliminated these issues. The following article reviews the most common complications following PRP treatment, including reported occurrences, inciting factors, and underlying pathophysiology.
[Mh] Termos MeSH primário: Fotocoagulação/efeitos adversos
Procedimentos Cirúrgicos Oftalmológicos/efeitos adversos
Complicações Pós-Operatórias
Doenças Retinianas/cirurgia
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1080/08820538.2017.1353820



página 1 de 1771 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde